Why Wall Street Gave Up on Pfizer—and Why That May Be a Mistake

Key Points

• Pfizer trades at a historic discount compared to its peers while paying a dividend yield that significantly outperforms the broader market average.
• Strategic acquisitions have established a robust pipeline of next-generation cancer treatments, which are driving growth.
• Management has aggressively re-entered the weight-loss market with new assets, including one that offers a convenient monthly dosing schedule for patients.

The market of 2025 will be remembered for its extremes. While investors poured billions into technology sector giants and companies manufacturing weight-loss drugs, traditional pharmaceutical leaders were left in the cold. Nowhere is this more evident than with Pfizer Inc. NYSE: PFE. Trading near multi-year lows around $25, the company finishes the year as one of the most unloved assets in the S&P 500.

For the casual observer, the pessimism seems justified, as the firm has spent the last two years battling a perfect storm.

Revenue from COVID-19 products vanished faster than anticipated, high-profile pipeline candidates failed in clinical trials, and activist investors launched a public campaign against the management team.

However, smart investing often requires venturing where others refuse to go. With the exit of activist investor Starboard Value in November and a realistic reset of financial guidance, the storm appears to have passed.

The bad news is out, and Pfizer’s stock price has likely found its floor. As we enter 2026, Pfizer presents a rare scenario: a blue-chip company trading at a severely distressed price, offering a solid dividend yield while it quietly rebuilds its future.

The Mathematical Case: Why the Price Is Wrong

For value investors, the argument for Pfizer is grounded in simple mathematics. The market is currently pricing the company as if its earnings will permanently shrink, creating a stark disconnect between the share price and the company's actual cash generation.

A Historic Valuation Gap

Pfizer currently trades at a forward price-to-earnings ratio (P/E) of approximately 8.6x. To understand how affordable this is, you must compare it to the competition. The average company in the pharmaceutical sector trades at a multiple of 15x to 20x earnings. High-growth competitors like Eli Lilly NYSE: LLY trade at multiples significantly higher than that.

When a company trades at 8.6x earnings, the market is essentially saying it has zero expectations for growth. This creates a low bar for success. Pfizer does not need to produce a miracle to see its stock rise; it simply needs to prove that its business is stable. Any positive earnings surprise could trigger a multiple expansion, in which the stock price increases simply to catch up with the industry average.

The Dividend Shield

While investors wait for this repricing to happen, they are paid handsomely to hold the stock.

• Annual Payout: $1.72 per share.
• Current Yield: Approximately 6.9%.

This yield is nearly four times higher than the S&P 500 average. It acts as a margin of safety. Even if the stock price remains flat throughout 2026, a nearly 7% dividend yield alone provides a solid baseline return that beats most savings accounts and government bonds.

Furthermore, management is securing this dividend through a $4 billion cost-saving initiative.

By cutting administrative bloat and optimizing manufacturing, they are preserving the cash flow needed to keep those quarterly checks clearing.

The New Foundation: Oncology Takes the Lead

The most common criticism of Pfizer is that it has a growth gap left behind by the decline of its COVID business. To fill this hole, the company has pivoted aggressively toward oncology (cancer treatments). 

The Guided Missile Technology

The jewel of Pfizer’s 2023 Seagen acquisition is its leadership in Antibody-Drug Conjugates (ADCs). Traditional chemotherapy is like a wide blast that damages both healthy and cancerous cells. ADCs are more like guided missiles. They are engineered to identify specific cancer cells and deliver a toxic payload directly, sparing healthy tissue.

This technology is already generating results. The Seagen portfolio contributed approximately $3.4 billion in revenue in 2024, and delivered $2.75 billion in the first three quarters of 2023, driven by strong sales of Padcev for bladder cancer.

Navigating the Bumps

The path hasn't been perfectly smooth. In December 2025, the company reported a safety signal regarding Hympavzi, a hemophilia treatment, involving a patient death in a trial extension. While this news caused a temporary jitter in the stock, it does not derail the broader thesis. The oncology portfolio is deep, with over 60 programs in development. Additionally, the company recently reinforced its pipeline by licensing a promising bispecific antibody from 3SBio, underscoring its ongoing effort to reload the chamber with new potential blockbusters.

Catching Up: The Strategy for Weight Loss

In early 2025, Wall Street wrote Pfizer off as a loser in the lucrative weight-loss drug race after its internal pill, Danuglipron, failed to progress. However, giving up on the biggest medical trend of the decade was never an option. In late 2025, Pfizer executed a strategic pivot, buying its way back into the game through two major deals.

The Injectable Strategy (Metsera)

In November, Pfizer acquired Metsera for approximately $7 billion. This deal gave them immediate ownership of a next-generation injectable drug (MET-097i). Unlike the current market leaders that require weekly injections, this candidate has the potential to be administered monthly, offering a significant convenience advantage for patients.

The Oral Strategy (YaoPharma)

Recognizing that some patients prefer pills over needles, Pfizer also signed a licensing deal with YaoPharma for a small-molecule GLP-1 candidate.

Why This Matters

Currently, Pfizer’s stock price reflects zero value for its obesity pipeline. The market assumes they have lost. This creates a free option for investors. Because expectations are at rock bottom, any clinical success from the Metsera or YaoPharma assets represents pure upside to the stock price. Pfizer doesn't need to be first; it just needs to capture a slice of what is predicted to be a $100 billion market.

The Risk/Reward Equation: 2026 Belongs to Value

Pfizer enters the new year as a company in transition, but one with a heavily fortified bottom line. Management has set a revenue floor of approximately $61 billion for 2026. This is a realistic, achievable target that removes the uncertainty that plagued the stock in previous years.

For investors, the equation is simple. At $25 per share, the downside risk is cushioned by a healthy dividend yield and a valuation already at historic lows. The upside, however, is significant. If the oncology portfolio continues to grow, or if the new weight-loss drugs show promise in clinical trials, the stock could see a sharp repricing.

The unloved stocks of one year often become the standout performers of the next. With the activist drama over and the balance sheet stabilized, the company has transitioned from a falling knife to a foundational holding for value-oriented portfolios. For Pfizer, 2026 may be the year the sleeping giant wakes up.